Study #2024-0443
A phase Ia/Ib study of NMS-03597812 in adult patients with relapsed/refractory acute myeloid leukemia including patients with TP53 mutations
MD Anderson Study Status
Enrolling
Treatment Agent
NMS-03597812
Description
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-855-927-2548
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.